<DOC>
	<DOCNO>NCT01641133</DOCNO>
	<brief_summary>The primary aim study assess reactogenicity Synflorix™ vaccine Prevenar 13™ vaccine primary vaccination 2 4 month age either Synflorix™ Prevenar 13™ vaccine Prevenar 13™ Synflorix™ , respectively . In addition , study aim assess safety , reactogenicity , immunogenicity antibody persistence ( approximately 8-11 month follow primary vaccination ) Synflorix™ vaccine Prevenar 13™ vaccine primary vaccination 2 4 month age either Synflorix™ Prevenar 13™ vaccine Prevenar 13™ Synflorix™ , respectively . This study also aim assess safety , reactogenicity immunogenicity Synflorix™ vaccine give booster dose 12-15 month age follow primary vaccination 2 4 month age either Synflorix™ vaccine Prevenar 13™ vaccine Prevenar 13™ Synflorix™ , respectively .</brief_summary>
	<brief_title>Primary Vaccination With Either Synflorix™ Prevenar 13™ Both Vaccines Booster Vaccination With Synflorix™</brief_title>
	<detailed_description>This study partially blind primary phase conduct observer-blind method booster phase open method .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol . A male female , include , 612 week age time first vaccination . Healthy subject establish medical history clinical examination enter study . Born gestation period least 36 week . Written inform consent obtain parent ( ) /LAR ( ) subject . Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use entire study period . Chronic administration immunosuppressant immunemodifying drug since birth plan use study . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component study vaccine . Major congenital defect serious chronic illness . History seizures progressive neurological disease . Administration immunoglobulins and/or blood product since birth plan use study . Acute disease and/or fever time enrolment . Previous vaccination plan vaccination study pneumococcal vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pneumococcal conjugate vaccine</keyword>
	<keyword>Synflorix™</keyword>
	<keyword>Prevenar 13™</keyword>
	<keyword>Pneumococcal disease</keyword>
</DOC>